Abbott Laboratories $ABT Shares Sold by Clifford Swan Investment Counsel LLC

Clifford Swan Investment Counsel LLC cut its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 1.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 209,323 shares of the healthcare product maker's stock after selling 2,761 shares during the period. Abbott Laboratories accounts for about 1.0% of Clifford Swan Investment Counsel LLC's holdings, making the stock its 29th biggest position. Clifford Swan Investment Counsel LLC's holdings in Abbott Laboratories were worth $28,470,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its stake in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after acquiring an additional 4,755 shares during the last quarter. GAMMA Investing LLC increased its stake in Abbott Laboratories by 17.0% in the 1st quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker's stock valued at $5,103,000 after buying an additional 5,590 shares during the period. GHP Investment Advisors Inc. raised its position in Abbott Laboratories by 3.4% during the 1st quarter. GHP Investment Advisors Inc. now owns 29,491 shares of the healthcare product maker's stock worth $3,912,000 after buying an additional 959 shares during the last quarter. Moran Wealth Management LLC acquired a new stake in shares of Abbott Laboratories in the 1st quarter worth $10,015,000. Finally, Strategic Investment Advisors MI boosted its position in Abbott Laboratories by 2.1% during the first quarter. Strategic Investment Advisors MI now owns 7,431 shares of the healthcare product maker's stock worth $986,000 after purchasing an additional 155 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on ABT shares. William Blair raised Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Barclays lifted their target price on shares of Abbott Laboratories from $159.00 to $162.00 and gave the stock an "overweight" rating in a research report on Friday, October 17th. Weiss Ratings reissued a "buy (b)" rating on shares of Abbott Laboratories in a research note on Wednesday, October 8th. BTIG Research reiterated a "buy" rating and set a $145.00 target price on shares of Abbott Laboratories in a report on Wednesday, October 15th. Finally, Raymond James Financial increased their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an "outperform" rating in a research note on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $147.00.

Abbott Laboratories Price Performance

ABT opened at $127.83 on Thursday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The firm has a market cap of $222.48 billion, a price-to-earnings ratio of 16.02, a PEG ratio of 2.42 and a beta of 0.69. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a fifty day simple moving average of $132.25 and a 200 day simple moving average of $131.52.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting analysts' consensus estimates of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The company had revenue of $11.37 billion during the quarter, compared to analysts' expectations of $11.40 billion. During the same period in the prior year, the company posted $1.21 EPS. The firm's revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.